Somatic genetic alterations in synchronous and metachronous low‐grade serous tumours and high‐grade carcinomas of the adnexa
Histopathology2018Vol. 74(4), pp. 638–650
Citations Over TimeTop 15% of 2018 papers
Rajmohan Murali, Pier Selenica, David N. Brown, R. Keira Cheetham, Raghu Chandramohan, Nidia Claros, Nancy Bouvier, Donavan T. Cheng, Robert A. Soslow, Britta Weigelt, W. Glenn McCluggage
Abstract
Our results suggest that progression from SBT to HGSC may take place in a subset of cases, and that at least some of the rare HGSCs lacking TP53 mutations may be derived from a low-grade serous precursor.
Related Papers
- → Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).(2013)43 cited
- → Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma(2012)24 cited
- → Not all RAS mutations created equal: Functional and clinical characterization of 80 different KRAS and NRAS mutations.(2017)10 cited
- → RAS status in Korean patients with stage III and IV colorectal cancer(2015)7 cited
- → RAS mutations distribution in a 108 patients series of colorectal cancer(2014)